A 54-year-old woman presented with a severe autoimmune anemia, thrombocytopenia, neutropenia (Evans' syndrome), and CD8
Introduction
For several years the nomenclature of chronic T cell proliferative disease has been an issue of controversy and debate. Initially this disease entity was described as chronic lymphocytic leukemia of T cell origin (T-CLL), 1 T␥-lymphocytosis, 2 or large granular lymphocyte (LGL) leukemia. 3, 4 Chronic T cell proliferative disease is relatively rare and has a heterogeneous clinical presentation, but with common immunological and morphological characteristics, which should be discriminated from other mature T cell malignancies such as T cell prolymphocytic leukemia, adult T cell leukemia-lymphoma, and Séz-ary syndrome. In a recent review on this subject Loughran 5 proposed a unifying terminology discerning two major subgroups: T-LGL leukemia, characterized by clonal CD3
+ LGL proliferation of mature T-lymphocyte origin and NK-LGL leukemia, characterized by CD3 − LGL proliferation of natural killer (NK) cell origin.
Although knowledge about classification, clinical course, and prognosis is increasing, much has to be learned about clinical intervention and therapeutic options. In a worldwide multicenter study the clinical course of 151 patients was described and unfavorable factors were analyzed. The prognosis varied from spontaneous regression to progressive, fatal disease. 6 Therapeutic interventions were incidental, empiric and with disappointing results: neither steroids (21 cases), nor chemotherapy (24 cases), nor splenectomy (12 cases) seemed to alter the clinical outcome efficiently. 6 Here we describe a patient whose T-LGL leukemia with refractory anemia, thrombocytopenia and neutropenia did not 
Materials and methods

Immunophenotyping
Mononuclear cells (MNC) were isolated by Ficoll (sm: 1077 g/l) density centrifugation and subjected to immunophenotyping with direct and indirect antibody stainings. These antibodies concerned: CD1 (66IIC7), CD2 (T11), CD3 (Leu-4), CD4 (Leu-3a), CD5 (Leu-1), CD6 (OKT17), CD7 (3A1), CD8 (Leu-2a), CD10 (VIL-A1), CD11b (OKM1), CD11c (Leu-M5), CD14 (My4), CD15 (VIM-D5), CD16 (Leu-11b, Leu-11c, GRM-1, CLB FcR gran/1, and 3G8), CD19 (B4), CD20 (B1), CD25 (2A3), CD56 (Leu-19), CD57 (Leu-7), anti-Ig, anti-Ig, anti-T cell receptor (TCR)␣␤ (BMA031), anti-TCR␥␦ (11F2), and anti-HLA-DR (L243 8 In addition we used a large panel of more than 50 antibodies against variable domains of TCR␤ chains (V␤ antibodies), which were kindly provided by Immunotech (Marseille, France), T-Cell Diagnostics (Woburn, MA, USA), and T Cell Sciences (Cambridge, MA, USA). These V␤ antibodies were used for studying clonality at the TCR␤ protein chain level. 9 
Southern blot analysis of TCR␤ genes
For studying clonality at the DNA level, Southern blot analysis of TCR␤ genes was performed. DNA was isolated from MNC by use of phenol-chloroform extraction as described, 10 digested with EcoRI or HindIII, size-separated in 0.7% agarose gels, and blotted to nylon membranes, which were successively hybridized to 32 P-random oligonucleotide labeled J␤1 (TCRBJ1), J␤2 (TCRBJ2), and C␤ (TCRBC) probes. 10 After stringent washing the filters were exposed to X-ray films for detection of probe hybridization.
Case report
Patient P was already known to our hospital since 1978 because of severe atherosclerosis of her mesenteric arteries, which made vascular reconstruction necessary several times. She was a heavy smoker.
At age 54 she was hospitalized in 1991 because of severe anemia. She had a history of progressive tiredness for some weeks without complaints of infection, fever, hemorrhage, weight loss, night sweats, or arthritic disease. Physical examination did not reveal lymphadenopathy or splenomegaly. Laboratory evaluation showed severe megaloblastic anemia (hemoglobin concentration 4.8 mmol/l, hematocrit 0.20, MCV 118 fl), thrombocytopenia (32 × 10 9 /l) and relative neutropenia (white cell count 4.7 × 10 9 /l with a differential count of 44% neutrophils, 1% band forms, 1% myelocytes, 51% lymphocytes and 3% monocytes) (total lymphocyte count: 2.4 × 10 9 /l). Other laboratory values included a reticulocyte count of 89.6 × 10 9 , an erythrocyte sedimentation rate of 95 mm/h, a total bilirubin of 18 mol/l, a lactate dehydrogenase of 435 U/l, a reduced serum haptoglobin (Ͻ0.05 mg/ml) and a hemoglobinuria (35 mol/l). The electrolytes, creatinine, other liver enzymes, clotting tests, vitamin B 12 , folate and ferritin were within the normal range. The direct Coombs test was positive, as was the test for anti-platelet and anti-granulocyte antibodies. Tests for anti-nuclear antibodies, rheumatoid factor, and antibodies to HIV, HLTV-I/II or Herpes-6 were negative. Test for antibodies to parvovirus (B19) was positive (IgG). Bone marrow was difficult to aspirate and was combined with bone marrow biopsy: it showed a strong reticular staining with a normoblastic erythroid hyperplasia, lymphocytosis, normal megakaryocytosis, and decreased myelopoiesis without signs of myelofibrosis or dysplasia. Immunophenotyping of peripheral blood MNC in March 1991 revealed approximately 25% B-lymphocytes with a normal Ig light chain distribution (/ ratio: 1.2) and approximately 70% T-lymphocytes with a slightly decreased CD4/CD8 ratio of 0.8 (Table 1) . Radiographic examination with ultrasonography and CT scan of chest and abdomen did not show enlarged lymphoid organs. At that moment a diagnosis was made of autoimmune hemolytic anemia with autoimmune thrombocytopenia, and relative neutropenia, also called Evans' syndrome. 11 Treatment with corticosteroids was started (1.5 mg prednisone per kg daily).Nevertheless, several transfusions with erythrocytes and platelets were needed and 51 Cr red cell and platelet survival studies still showed reduced survival times for both erythrocytes (13 days) and platelets (1.5 days); splenectomy was performed at 6 months after the initial presentation (Figure 1) . The spleen had a total weight of 80 g (normal approximately 150 g) and histological examination showed no abnormalities except some extramedullary erythropoiesis. Transient clinical improvement was seen with reoccurrence of hemolytic anemia and thrombocytopenia after a few months. Treatment with cyclophosphamide was initiated (150 mg daily), but no clinical improvement was seen.
Immunophenotyping 
/CD8
+ T-lymphocytes were positive for CD16 (all tested antibodies) and partly expressed CD11b and HLA-DR, but were negative for CD11c, CD25, CD56, and CD57. Southern blot analysis of the TCR␤ genes revealed one deleted and one clonally rearranged J␤1 region and biallelic clonal J␤2 rearrangements (Figure 2A normally found in less than 3% of blood T-lymphocytes ( Figure 2B ). Peripheral blood smears were revised and now clearly showed several large granular lymphocytes (Figure 3 ).The initial diagnosis was modified to T-LGL leukemia with accompanying Evans' syndrome. Treatment of this disease was not established at that moment and after informed consent a course with cyclosporin A was tried empirically. During a period of 23 months prior to start of cyclosporin therapy a total of 69 units of red cell transfusions and 24 units of platelet transfusions had been given to maintain the hemoglobin concentration at a level of 6 mmol/l and to prevent severe hemorrhage. In January 1993 cyclosporin A was started at a daily dose of 300 mg (6 mg/kg), titrated to an average blood concentration of 600 g/l. Within 1 month after start of treatment, elevations of both platelet counts and hemoglobin values were seen ( Figure 1A ) and normal hematological values were reached within 6 months. The numbers of lymphocytes had declined to 28% (or 1.7 × 10 9 /l) and subsequently remained stable at normal levels ( Figure 1B) . Regular immunophenotyping in June 1993, August 1994, and June 1995 did not disclose abnormal T cell populations, but Southern blot analysis still showed the presence of clonal rearrangements ( Table 1) . Reactivation of the T-LGL leukemia was seen when the cyclosporin dosage fell below 50 mg twice a day (plasma concentration of 25 g/l): thrombocytopenia reappeared ( Figure 3A) . Southern blot analysis showed an increase in the density of the rearranged TCR␤ gene bands. This increase was not obviously detectable by routine immunophenotyping (Table 1) . With a cyclosporin dosage of 100 mg twice a day clinical remission was reinduced.
Flow cytometry with V␤ antibodies in June 1995 enabled us to estimate the aberrant number of V␤7.1 expressing
+ T-lymphocytes to be 0.43 × 10 9 /l (approximately 23% of CD3 + lymphocytes) ( Figure 4 ) and allowed us to follow this 'tumor load' prospectively and to titrate the cyclosporin dosage accordingly (Table 1) . In February 1996 again hemolytic anemia developed and it appeared that her leukemic tumor load had been tripled to 0.95 × 10 9 cells/l. At that moment a diagnosis of a poorly differentiated squamous cell carcinoma of the right lung was made. A successful lobectomy was performed, but 1 week after the operation bacteremia with ␣-hemolytic Streptococci developed and she died of an uncontrollable sepsis.
Discussion
Our patient presented with classical Evans' syndrome (autoimmune hemolytic anemia and thrombocytopenia without signs of systemic autoimmune disease) and we therefore focused our therapy initially on this diagnosis. However, treatment with high-dose steroids, splenectomy and immunosuppressive drugs did not achieve any clinical improvement. Exploring the marked lymphocytosis in more detail led us to the diagnosis of monoclonal CD8 + T-lymphocytosis. Recently 
/ TCR␣␤
+ immunophenotype and contained biallelic clonally rearranged TCR␤ genes. Additional immunophenotyping with more than 50 V␤ antibodies further demonstrated the clonal character of the CD8 + T-lymphocytes, because they only expressed V␤7.1 (Figure 2) . The clinical picture of autoimmune hemolytic anemia, thrombocytopenia, and (relative) neutropenia is recognized as a common presentation of T-LGL leukemia and also our initial difficulty in aspirating bone marrow fits this picture. 5 The clinical course of T-LGL leukemia is uncertain and mortality may be as high as 20% in 4 years, no matter which treatment is given. 6 Although refractory anemia and thrombocytopenia were not distinguished as unfavorable prognostic factors in a large multicenter study, 6 the clinical condition of our patient deteriorated progressively, prompting therapeutic intervention. Treatment with high-dose steroids, splenectomy, and conventional immunosuppressive drugs was unsuccessful. At that time therapeutic inverventions for T-LGL leukemia had all been empirical and the experiences had been limited and variable. We decided to try a treatment course with cyclosporin A as was suggested by Garipidou et al. 12 A remarkable recovery to complete clinical remission was seen soon after initiation of cyclosporin. In contrast to Garipidou et al who maintained the cyclosporin dose at 400-600 mg daily, we tapered the dosage stepwise. Although we were able to control her leukemia for almost 3. years, she unfortunately died of an uncontrollable sepsis shortly after the diagnosis of pulmonary cancer. We believe that sepsis was specially related to the splenectomized state of our patient and that the development of the pulmonary cancer was more related to her heavy smoking habit than to the use of cyclosporin.
The retrospective finding that the TCR␣␤ + T-LGL cells in our patient expressed V␤7.1 appeared to be helpful for monitoring the effectiveness of the treatment, because V␤7.1/CD8/CD3 triple immunological stainings allowed an easy and rapid detection of the T-LGL cells in a prospective fashion (Figure 4 and Table 1 ). The detection limit of this triple staining is approximately 5%, which is comparable to the detection limit of the time-consuming Southern blot technique.
To our knowledge this is the fifth LGL patient who has been successfully treated with cyclosporin A. [12] [13] [14] [15] Although low-dose methotrexate was recently demonstrated to be effective in 50% of patients with T-LGL leukemia (n = 10), 16 further evaluation of cyclosporin A treatment in LGl appears to be of interest.
